GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » Additional Paid-In Capital

Ascentage Pharma Group International (FRA:36X) Additional Paid-In Capital : €858.5 Mil(As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Ascentage Pharma Group International Additional Paid-In Capital?


Ascentage Pharma Group International's quarterly additional paid-in capital increased from Dec. 2023 (€764.3 Mil) to Jun. 2024 (€831.1 Mil) and increased from Jun. 2024 (€831.1 Mil) to Dec. 2024 (€858.5 Mil).

Ascentage Pharma Group International's annual additional paid-in capital increased from Dec. 2022 (€730.2 Mil) to Dec. 2023 (€764.3 Mil) and increased from Dec. 2023 (€764.3 Mil) to Dec. 2024 (€858.5 Mil).

Ascentage Pharma Group International Additional Paid-In Capital Historical Data

The historical data trend for Ascentage Pharma Group International's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascentage Pharma Group International Additional Paid-In Capital Chart

Ascentage Pharma Group International Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only 519.20 742.27 730.24 764.29 858.52

Ascentage Pharma Group International Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 730.24 764.59 764.29 831.07 858.52

Ascentage Pharma Group International Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Ascentage Pharma Group International Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Ascentage Pharma Group International's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascentage Pharma Group International Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascentage Pharma Group International (FRA:36X) » Definitions » Additional Paid-In Capital
Comparable Companies
HKSE:09606 HKSE:01952 HKSE:09969 HKSE:02696 HKSE:06826 HKSE:02171 HKSE:02162 HKSE:01548 HKSE:09966 HKSE:02410 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
AAPG:USA 06855:Hong Kong 36X:Germany
Address
68 Xinqing Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215000
Website
https://www.ascentagepharma.com
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.

Ascentage Pharma Group International Headlines

No Headlines